Edesa Biotech, Inc. SEC filings EDSA
Edesa Biotech, Inc. has 751 filings in SEC EDGAR's recent list, going back to Feb 3, 2012. Its latest annual report, Form ARS, was filed on Apr 3, 2026 for the period ended Sep 30, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (officer or director change). The company's fiscal year ends on September 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jul 13, 2026 | — |
| D | Filing | Jun 26, 2026 | — |
| EFFECT | Filing | Sep 9, 2025 | — |
| CORRESP | Letter to the SEC | Sep 5, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 30, 2025 | — |
| EFFECT | Filing | Mar 11, 2025 | — |
| CORRESP | Letter to the SEC | Mar 7, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 7, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 4, 2025 | — |
| CORRESP | Letter to the SEC | Feb 26, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 20, 2025 | — |
| D | Filing | Feb 14, 2025 | — |
| EFFECT | Filing | Dec 23, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 21, 2022 | — |
| CORRESP | Letter to the SEC | Dec 21, 2022 | — |
| EFFECT | Filing | Aug 12, 2022 | — |
| CORRESP | Letter to the SEC | Aug 10, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 9, 2022 | — |
| EFFECT | Filing | Apr 19, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 15, 2022 | — |
| CORRESP | Letter to the SEC | Apr 15, 2022 | — |
| D | Filing | Apr 5, 2022 | — |
| EFFECT | Filing | Mar 6, 2020 | — |
| CORRESP | Letter to the SEC | Mar 4, 2020 | — |
| UPLOAD | Letter from the SEC | Feb 27, 2020 | — |
| EFFECT | Filing | Sep 12, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 10, 2019 | — |
| CORRESP | Letter to the SEC | Sep 10, 2019 | — |
| EFFECT | Filing | Dec 10, 2018 | — |
| EFFECT | Filing | Dec 10, 2018 | — |
| EFFECT | Filing | Jun 15, 2018 | — |
| UPLOAD | Letter from the SEC | Jun 14, 2018 | — |
| CORRESP | Letter to the SEC | Jun 13, 2018 | — |
| EFFECT | Filing | May 10, 2018 | — |
| CORRESP | Letter to the SEC | May 9, 2018 | — |
| CORRESP | Letter to the SEC | May 7, 2018 | — |
| UPLOAD | Letter from the SEC | May 1, 2018 | — |
| EFFECT | Filing | Sep 28, 2016 | — |
| CORRESP | Letter to the SEC | Sep 26, 2016 | — |
| UPLOAD | Letter from the SEC | Sep 23, 2016 | — |
| D | Filing | Jul 21, 2016 | — |
| CT ORDER | Filing | Jul 7, 2016 | — |
| CERTNAS | Auto-generated paper document | Nov 4, 2015 | — |
| 8-A12B | Stellar biotechnologies, inc. form 8-a | Nov 3, 2015 | — |
| EFFECT | Filing | May 8, 2015 | — |
| CT ORDER | Filing | Dec 20, 2013 | — |
| D/A | Filing | Oct 3, 2013 | — |
| D | Filing | Sep 3, 2013 | — |
| D | Filing | Apr 11, 2013 | — |
| D | Filing | Jan 15, 2013 | — |
| NT 20-F | Stellar form 12b25 | Dec 31, 2012 | Aug 31, 2012 |
| D | Filing | Oct 31, 2012 | — |
| CT ORDER | Filing | Aug 7, 2012 | — |
| UPLOAD | Letter from the SEC | Aug 6, 2012 | — |
| 20FR12G/A | Stellar form 20-f registration statement amendment no. 3 | Jul 9, 2012 | — |
| 20FR12G/A | Stellar form 20-f registration statement amendment no. 2 | Jul 5, 2012 | — |
| UPLOAD | Letter from the SEC | May 14, 2012 | — |
| 20FR12G/A | Stellar form 20-f amendment #1 | Apr 30, 2012 | — |
| UPLOAD | Letter from the SEC | Mar 1, 2012 | — |
| 20FR12G | Stellar biotechnologies form 20-f registration statement | Feb 3, 2012 | — |
Showing 60 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EDSA (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- British Columbia, Canada
- Headquarters
- Toronto
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1540159
- Former names
- Stellar Biotechnologies, Inc. (until May 30, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.